

Subst. Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Patent Number (Optional)
56290-054
CROL-132CP

Application Number
09/647,726

Applicant
Kevin R. Stone et al.

Filing Date
12/4/00

Group Art Unit
3738

U. S. Patent Documents

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
VA	A-29	5,865,849	2/99	Stone	623	18	
↑	A-30	5,902,338	5/99	Stone	623	13	
	A-31	5,904,716	5/99	Gendler	623	11	
	A-32	5,922,027	7/99	Stone	623	11	
	A-33	5,944,755	8/99	Stone	623	16	
	A-34	5,984,858	11/99	Stone	600	20	
	A-35	6,046,379	4/00	Stone et al.	623	11	
	A-36	6,049,025	4/00	Stone et al.	128	898	
VA	A-37	6,110,206	8/00	Stone	623	13.11	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
VA	B-1	WO 8403036	8/84	PCT				
↑	B-2	WO 95/28412	10/95	PCT				
	B-3	WO 95/33828	12/95	PCT				
	B-4	WO 95/26740	10/95	PCT				
VA	B-5	EP 347,496	12/89	EP				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

VA	C-1	Rodrigo et al., "Osteocartilaginous Allografts as Compared with Autografts in the Treatment of Knee Joint Osteocartilaginous Defects in Dogs", Clinical Orthopedics and Related Research, 134, pp. 342-349 (1978).
↑	C-2	Webber et al., "Cell Culture of Rabbit Meniscal Fibrochondrocytes: Proliferative and Synthetic Response to Growth Factors and Ascorbate", Journal of Orthopedic Research, 3, pp. 36-42 (1985).
	C-3	Collins et al., "Characterization of Porcine Endothelial Cell Determinants Recognized by Human Natural Antibodies", Xenotransplantation, 1, pp. 36-46 (1994).
VA	C-4	LaVecchio et al., "Enzymatic Removal of Alpha-Galactosyl Epitopes From Porcine Endothelial Cells Diminishes The Cytotoxic Effect of Natural Antibodies", Transplantation, 60, pp. 841-847 (1995).

EXAMINER
V. Anumora


DATE CONSIDERED
8/27/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.

Subst. Form PTO-1449			Docket Number (Optional) 56290-054 CROL-132CP	Application Number 09/647,726
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>			Applicant Kevin R. Stone et al.	
			Filing Date 12/4/00	Group Art Unit 3738
LA	C-18	J.M. Lane, et al., "Current Approaches to Experimental Bone Grafting", Orthopedic Clinics of North America 18, pp. 213-225 (1987)		
↑	C-19	U. Galili et al., "Interaction Between Human Natural Anti- α -Galactosyl Immunoglobulin G and Bacteria of The Human Flora", Infect. Immun. 56, 1730-1737 (1988)		
	C-20	R.M. Hamadeh et al., "Human Natural Anti-Gal IgG Regulates Alternative Complement Pathway Activation on Bacterial Surfaces", J. Clin. Invest. 89, 1223-1235 (1992)		
	C-21	M. Sandrin et al., "Anti-Pig IgM Antibodies in Human Serum React Predominantly With Gal (α 1-3) Gal Epitopes", Proc. Natl. Acad. Sci USA 90, 11391-11395 (1993)		
	C-22	H. Good et al., "Identification of Carbohydrate Structures That Bind Human Antiporcine Antibodies: Implications for Discordant Xenografting In Humans", Transplant. Proc. 24, 559-562 (1992)		
	C-23	B.H. Collins, et al., "Cardiac Xenografts Between Primate Species Provide Evidence for the Importance of the α -Galactosyl Determinant in Hyperacute Rejection, J. Immunol. 154, 5500-5510 (1995)		
	C-24	S. Stevenson, et al., "The Effect of Osteogenin (a Bone Morphogenetic Protein) on the Formation of Bone in Orthotopic Segmental Defects in Rats", Journal of Bone and Joint Surgery No. 76, 1676-1687 (1994)		
	C-25	J. Feighan, et al., "Induction of Bone by a Demineralized Bone Matrix Gel: A Study in a Rat Femoral Defect Model", Journal of Orthopaedic Research 13, 881-891 (1995).		
↓ VA	C-26	R.G. Spiro et al., "Occurrence of α -D-Galactosyl Residues in the Thyroglobulin from Several Species. Localization in the Saccharide Chains of the Complex Carbohydrate Units, J. Biol. Chem. 259, 9858-9866 (1984).		
	C-27	R.G. Arumugham et al., "Structures of the Asparagine-Linked Sugar Chains of Laminin", Biochem. Biophys. Acta 883, 112-126 (1986).		
EXAMINER	V. Arumugham		DATE CONSIDERED 8/27/02	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.				

RECEIVED
 FEB 13 2001
 TO 3700 MAIL ROOM

Paper #5

Subst. Form PTO-1449				Docket Number (Optional) 56290-054 CROL-132CP		Application Number 09/647,726		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Applicant Kevin R. Stone et al.				
				Filing Date 12/4/00		Group Art Unit 3738		
U. S. Patent Documents								
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	VA	A-1	4,400,833	8/83	Kurland	3	1	
	↑	A-2	4,585,585	4/86	Waite	260	112.5R	
		A-3	4,597,266	7/86	Entrekin	62	46	
		A-4	4,609,627	9/86	Goldstein	435	269	
		A-5	4,627,853	12/86	Campbell et al.	623	16	
		A-6	4,642,120	2/87	Nevo et al.	623	16	
		A-7	4,678,470	7/87	Nashef et al.	623	16	
		A-8	4,755,593	7/88	Lauren	530	356	
		A-9	4,789,663	12/88	Wallace et al.	514	21	
		A-10	4,801,299	01/89	Brendel et al.	623	1/02	
		A-11	4,880,429	11/89	Stone	623	18	
		A-12	4,932,973	06/90	Gendler	623	16	
		A-13	5,067,962	11/91	Campbell et al.	623	13	
		A-14	5,071,741	12/91	Brockbank	435	1	
		A-15	5,131,850	7/92	Brockbank	435	1	
		A-16	5,160,313	11/92	Carpenter et al.	600	36	
		A-17	5,171,660	12/92	Carpenter et al.	435	1	
		A-18	5,192,312	3/93	Orton	623	2	
		A-19	5,206,023	4/93	Hunziker	424	423	
		A-20	5,216,126	6/93	Cox et al.	530	350	
		A-21	5,306,304	4/94	Gendler	623	16	
		A-22	5,333,626	08/94	Morse et al.	128	898	
		A-23	5,516,532	5/96	Atala et al.	424	548	
		A-24	5,613,982	3/97	Goldstein	623	11	
		A-26	5,632,778	5/97	Goldstein	623	11	
		A-27	5,681,353	10/97	Li et al.	623	18	
	VA		A-28	5,782,915	7/98	Stone	623	11
	EXAMINER V. Afanador				DATE CONSIDERED 8/27/02			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.								

RECEIVED
 FEB 13 2001
 TC 3100 MAIL ROOM